COVID-19 vaccine CEOs vow to wait for phase 3 data before filing for approval How will COVID-19 vaccines be allocated? AHIP has some questions LabCorp to launch single home swab test spanning COVID-19, the flu & RSV Moderna, facing high expectations and fierce competition, won't meet Wall Street's COVID estimates: analyst Healthcare tracker: Senate to vote as early as this week on 'targeted' COVID-19 relief Biopharma roundup: Rival shots may take a bite out of Moderna's vaccine sales, analyst says; late-stage data on Moderna, Pfizer's shots unlikely before year-end: Fauci Catapult Health launches at-home preventive checkup service for employers CSL plots millions of doses of COVID-19 vaccine shots, including AstraZeneca's, for Aussie government AstraZeneca puts COVID-19 spin on heart disease awareness, Brilinta campaigns Sanofi's later-stage trials hardest hit by COVID-19: report Featured Story | By Nick Paul Taylor The CEOs of all the leading Western developers of COVID-19 vaccines have vowed to only file for FDA approval after demonstrating safety and efficacy in phase 3. The pledge comes amid reports that the Trump Administration is pushing for a vaccine to be approved before the November election. read more |
| |
|---|
|
Top Stories By Tina Reed Will healthcare workers be among the first in line once a COVID-19 vaccine is available? Will disease outbreaks be taken into account as vaccines are distributed? Exactly how will they be paid for to ensure they are available and accessible? Those are just among the questions raised by America's Health Insurance Plans (AHIP) regarding a preliminary framework for the equitable allocation of COVID-19 vaccines. read more By Conor Hale LabCorp announced plans to launch a new at-home COVID-19 diagnostic that allows people to also get tested for the flu and respiratory syncytial virus from a single sample. read more By Eric Sagonowsky Moderna and its investors amid the COVID-19 pandemic, starting with initial vaccine research back in January and progressing to a phase 3 trial this summer at record speed. Now, analysts with SVB Leerink think challenges and competition lie ahead, and they're cautioning investors to the risks. read more By Healthcare Staff Follow along with the latest COVID-19 news straight from the Fierce Healthcare team. read more By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner Moderna's vaccine may not meet Wall Street sales projections, one analyst said; plus, phase 3 data on Moderna and Pfizer's shots are unlikely to arrive before election day, Anthony Fauci said. Six Sanofi trials have taken a blow from COVID-19, GlobalData found. LabCorp plans to launch an at-home test for COVID-19 and other respiratory viruses. read more By Heather Landi Capitalizing on the demand for remote care solutions, Catapult Health has launched a virtual checkup program for employers that offers home-based preventive care for employees and family members. The service provides virtual checkups using telehealth, clinical diagnostic tools, and screenings for depression and COVID-19. read more By Kyle Blankenship Looking to secure enough doses of a COVID-19 vaccine frontrunner for its residents, the Australian government signed an expansive supply deal with British drugmaker AstraZeneca last month. The Aussies then tapped local drugmaker CSL to chip in on production—and the initial order will tally up to the tens of millions of jabs. read more By Beth Snyder Bulik Too many heart attack victims are not going to the hospital out of fear of catching COVID-19—and that's a problem AstraZeneca wants to fix. A new public service announcement starring celebrity spokesperson and heart attack survivor Bob Harper encourages viewers to call 911 at the first signs of heart attack symptoms. read more By Ben Adams Sanofi’s trials and attempts at getting new drugs and vaccines against the pandemic onto the market have been some of the hardest hit by COVID-19. read more |
